SGK3 and breast cancer: Moreover, a synergistic interaction between SGK3-PROTAC1 and BYL719 was demonstrated by CCK-8 assay, suggesting that SGK3 inhibitors should be promising treatment strategies for breast cancer patients who had developed resistance to alpelisib.